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Key Points 
Question: Are IL-6 and PRG4 potential novel tissue biomarkers of conjunctival 
fibrosis post glaucoma surgery? 
 
Findings: In this cross-sectional study, IL-6 and PRG4 expression were upregulated 
and downregulated, respectively, in fibrotic conjunctiva and correlated strongly with 
the number of glaucoma surgeries and logMAR visual acuity. 
 
Meaning: These results support IL-6 and PRG4 as potential novel tissue biomarkers of 
disease severity and prognosis in conjunctival fibrosis post glaucoma surgery.  
Longitudinal studies are needed to validate these potential biomarkers of fibrosis in the 
future. 
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Abstract 
Importance: Post-surgical fibrosis is the critical determinant of the long-term surgical 
success in glaucoma surgery but there are currently no reliable biomarkers to stratify 
the risk of scarring. 
 
Objective: To compare the clinical phenotype of patients with conjunctival fibrosis 
post glaucoma surgery with candidate gene expression tissue biomarkers of fibrosis. 
 
Design, Setting, and Participants: In this cross-sectional study, 42 patients were 
recruited at the time of glaucoma surgery from September 2014 to September 2016.  
The participants were divided into fibrotic participants (n = 28, 43.8 ± 3.6 years, 57% 
females, 79% Caucasians) and non-fibrotic participants (n = 14, 47.7 ± 6.9 years, 29% 
females, 64% Caucasians). 
 
Main outcomes and measures: Genotype-phenotype correlations of the IL-6 or PRG4 
gene and detailed clinical phenotype.  The IL-6 and PRG4 protein expression in 
conjunctival tissues was also assessed using in situ immunohistochemistry. 
 
Results: The fibrotic participants had marked bleb scarring and vascularization and 
worse logMAR visual acuity.  The central bleb area, bleb height, and bleb vascularity 
were 1.4 ± 0.1, 1.4 ± 0.1 and 3.4 ± 0.2, respectively.  The IL-6 gene was upregulated in 
fibrotic cell lines (0.040) compared to non-fibrotic cell lines (0.011), difference = 
0.029, 95% CI: 0.015-0.043, p = .003.  The PRG4 gene was also downregulated in 
fibrotic cell lines (0.002) compared to non-fibrotic cell lines (0.109), difference = 
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0.107, 95% CI: 0.104-0.110, p = .033.  We found a strong correlation between the IL-6 
gene and the number of glaucoma surgeries (r = .94, p <.001) and logMAR visual 
acuity (r = .64, p = .026).  There was also a moderate correlation between the PRG4 
gene and the number of glaucoma surgeries (r = -.72, p = .005) and logMAR visual 
acuity (r = -.62, p = .026). 
 
Conclusions and relevance: IL-6 and PRG4 represent potential novel tissue 
biomarkers of disease severity and prognosis in conjunctival fibrosis post glaucoma 
surgery.  Future longitudinal studies with multiple post-operative measures are needed 
to validate the predictive value of these potential biomarkers of fibrosis. 
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Introduction 
Fetal skin wound healing is scarless and fundamentally different from adult wound 
healing (1, 2).  Scarless fetal wound healing is characterized by little inflammation, 
minimal fibroblast proliferation and decreased levels of potent inflammatory cytokines, 
such as IL-6 (3).  IL-6 controls the effector characteristics of various T cell subsets, 
including Th17 cells, Th22 cells and certain IL-10 secreting subsets (4).  IL-6 also 
plays an important role in pulmonary fibrosis (5), peritoneal fibrosis (6), renal 
interstitial fibrosis (7), and cancer-associated fibroblasts (8). 
Scarless fetal wound healing is also associated with high levels of hyaluronic acid (9), 
which increases the expression of proteoglycan 4 (PRG4) (10).  PRG4, also known as 
lubricin, is a lubricating mucin-like glycoprotein that has been detected at the ocular 
surface (11).  PRG4 is downregulated in palmar fascia fibroblasts from patients with 
Dupuytren’s contracture (12).  Moreover, increasing PRG4 expression using 
recombinant human PRG4 (rhPRG4) treatment decreases alpha smooth muscle actin 
expression in lens epithelial cells activated with TGFβ2 and may prevent the full 
myofibroblast phenotype in posterior capsular opacification (13). 
Detailed clinical phenotyping and effective biobanking of large patient cohorts will be 
critical to study putative biomarkers of disease severity and prognosis in ocular fibrosis 
(14).  Afro-Caribbean patients have a strong genetic predisposition to ocular and keloid 
scarring (15).  Dupuytren’s contracture is also a familial disorder that is highly 
prevalent in individuals of Northern European descent (16).  However, there is a 
current lack of reliable biomarkers to stratify the risk of scarring in the eye.  Being able 
to predict patients’ risk of scarring and to tailor the antifibrotic treatment regimen to 
each individual patient will be an extremely useful tool clinically to prevent 
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undertreating or exposing them to unnecessary treatments with potential side effects.  
In this study, correlation of the clinical phenotype of patients with conjunctival fibrosis 
with altered gene expression revealed IL-6 and PRG4 as potential novel tissue 
biomarkers of fibrosis. 
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Methods 
Patient recruitment 
We recruited glaucoma patients at the time of surgery at the Moorfields Eye Hospital 
(London, UK) from September 2014 to September 2016.  All patients were recruited 
according to local ethics approval (REC reference 10/H0808/127) and the tenets of the 
Declaration of Helsinki.  All participants gave written informed consent after 
explanation of the nature and possible consequences of the study.  The inclusion 
criteria were: age (over 18 years) and patients planned to have glaucoma tube surgery.  
The exclusion criterion was previous conjunctival surgery other than glaucoma 
surgery. 
 
Clinical examination 
The participants were divided into two groups: participants who had previous 
glaucoma surgery and participants with no previous glaucoma surgery.  All study 
participants underwent a standardized ophthalmic examination prior to surgery.  This 
included best corrected visual acuity, intraocular pressure (IOP), lens status, and cup 
disc ratio.  We also collected detailed patient demographics including age, gender, 
ethnicity, and type of glaucoma. 
 
Moorfields Bleb Grading 
We assessed each study participant with previous glaucoma surgery using the 
Moorfields bleb grading system (17).  Central bleb area, maximal bleb area, and bleb 
height were graded on a scale of 1 to 5 (1 = 0%, 2 = 25%, 3 = 50%, 4 = 75%, 5 = 
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100%).  Bleb vascularity was graded on a scale of 1 to 5 (1 = avascular, 2 = normal, 3 
= mild, 4 = moderate, 5 = severe hyperaemia). 
 
Medical and surgical treatment 
We collected the number of anti-glaucoma eye drops, including beta blockers, 
prostaglandin analogues, carbonic anhydrase inhibitors, alpha agonists, pilocarpine, 
and the number of patients on oral acetazolamide.  We also recorded any previous 
surgical and laser treatments, including the number of trabeculectomies, glaucoma tube 
surgeries, and diode laser treatments. 
 
Fibroblast cell lines 
We established fibrotic fibroblast (FF) and non-fibrotic fibroblast (NF) primary cell 
lines from conjunctival tissues collected from study participants with previous 
glaucoma surgery and study participants with no previous glaucoma surgery, 
respectively.  The conjunctival tissues were mechanically dispersed and the tissue 
fragments were placed in tissue culture dishes with Dulbecco’s modified Eagle’s 
medium (DMEM, Invitrogen), 10% fetal calf serum, 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 2 mM L-glutamine at 37°C with 5% CO2 (18).  Following outgrowth 
from the explant, the fibroblasts were trypsinized and cultured routinely in the above 
medium.  Fibroblast cell lines in early passages 1-2 were used in the experiments. 
 
Real-Time quantitative PCR 
RT-qPCR reactions were performed using a Platinum quantitative PCR master mix 
(ThermoFisher Scientific, Hemel Hempstead, UK) on a CFX Real-Time PCR detection 
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system (Bio-Rad, Hemel Hempstead, UK).  The Taqman gene expression assays were 
IL-6 (Hs00985639_m1), PRG4 (Hs00981633_m1), and GAPDH (Hs02758991_g1) 
(ThermoFisher Scientific, UK).  All mRNA values were normalized relative to that of 
GAPDH and triplicate experiments were performed for each condition. 
 
Immunohistochemistry 
Fibrotic and non-fibrotic human conjunctival tissues were fixed in formalin for 24 
hours.  The samples were dehydrated through an alcohol gradient (70%, 95%, 100% 
Industrial Methylated Spirit IMS), followed by chloroform clearance on a Leica Peloris 
II tissue processing machine.  The samples were embedded in paraffin wax using a 
Sakura Tissue-Tek TEC embedding machine.  Tissue sections were cut on a Thermo 
Scientific HM340E manual rotary microtome at a section thickness of 3 µm using 
Feather S35 microtomy blades.  The sections were mounted on Leica Xtra Adhesive 
slides, air dried for 60 minutes, and heated for 60 minutes at 70°C prior to staining.  
The sections were dewaxed and stained on a Leica Bond-Max automated 
immunostainer.  The sections were incubated with IL-6 (1:400, rabbit polyclonal 
ab6672, Abcam, UK) or PRG4 (1:200, polyclonal rabbit HPA028523, Atlas, UK) 
antibody for 30 minutes at room temperature. 
 
Immunofluorescence 
FF and NF cell lines were seeded onto coverslips at 1 x 10
5 
cells/ well in 6-well plates.  
The cells were fixed with 4% paraformaldehyde for 15 minutes and incubated with 
blocking solution (PBS containing 10% normal goat serum/ 0.03% Triton X100) for 30 
minutes.  The cells were then incubated with primary antibodies against IL-6 (1:100, 
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ab6672, Abcam, UK) or PRG4 (1:100, HPA028523, Atlas, UK) for 2 hours, followed 
by Alexa 488-conjugated goat anti-rabbit IgG (H+L) (1:500, Thermo Fisher Scientific, 
UK) for 1 hour.  The coverslips were then rinsed with PBS and mounted onto slides 
with mounting medium (DAKO, UK) containing 10 g/ml 4',6-diamidino-2-
phenylindole (DAPI).  Three randomly chosen fields per sample were imaged at 20x 
magnification using a Leica DM4000B microscope.  Stained areas of IL-6 and PRG4 
were calculated using a bespoke image processing algorithm written in MATLAB.  
Each image was first converted into a greyscale image ranging from a level of 0 for 
black to 255 for white.  The maximum background greyscale level of each image was 
then identified and any greyscale value above it was considered as staining. 
 
Statistical analysis 
All graphs display mean and standard error of the mean (SEM).  Statistical analysis 
was performed using the Student’s t-test to calculate differences in individual p values.  
We performed genotype-phenotype comparisons using Spearman’s correlation of the 
IL-6 or PRG4 gene versus clinical parameters, such as bleb area, bleb height, bleb 
vascularity, number of glaucoma surgeries, age, intraocular pressure, logMAR visual 
acuity, cup disc ratio, and number of anti-glaucoma eye drops. 
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Results 
Patient demographics 
A total of 42 patients were recruited during the study period: 28 participants (67%) had 
previous glaucoma surgery (fibrotic group) and 14 participants (33%) had no previous 
glaucoma surgery (non-fibrotic group).  Most study participants were white 
Caucasians: 22 white Caucasians (79%), 4 Asians (14%), and 2 Afro-Caribbeans (7%) 
in the fibrotic group; 9 white Caucasians (64%), 4 Asians (29%), and 1 Afro-Caribbean 
(7%) in the non-fibrotic group (see eTable 1 in the Supplement).  There were no 
differences judged to be relevant in age with a mean age of 43.8 ± 3.6 years in the 
fibrotic participants and 47.7 ± 6.9 years in the non-fibrotic participants (p = .578).  
There were 43% males and 57% females in the fibrotic group and 71% males and 29% 
females in the non-fibrotic group. 
 
Clinical phenotype 
All participants in the previously operated group had marked bleb scarring and 
vascularization (Figure 1A).  Using the Moorfields Bleb Grading system, the central 
bleb area, maximal bleb area, bleb height, and bleb vascularity were 1.4 ± 0.1, 1.4 ± 
0.1, 1.4 ± 0.1 and 3.4 ± 0.2, respectively (Figure 1B).  The fibrotic participants had 
multiple glaucoma surgeries with a mean of 1.5 (range = 1 to 3).  Among the fibrotic 
group, there were 13 participants (47%) who had trabeculectomy surgery, 4 
participants (14%) who had glaucoma tube surgery, and 11 participants (39%) who had 
multiple glaucoma surgeries (see eTable 1 in the Supplement). 
The study participants in the fibrotic group had worse best-corrected visual acuity with 
a mean logMAR vision of 0.58 compared to 0.31 in the non-fibrotic group, difference 
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= 0.27, 95% CI: 0.11-0.42, p = .037 (Figure 2A).  The fibrotic and non-fibrotic 
participants had a mean pre-operative IOP of 22.3 and 27.1 mmHg, respectively, 
difference = 4.8, 95% CI: 1.8-9.1, p = .133 (Figure 2B).  The majority of participants 
had advanced disc cupping with a cup disc ratio of 0.87 and 0.84 in the fibrotic and 
non-fibrotic groups, respectively, difference = 0.03, 95% CI: -0.01-0.07, p = .350 
(Figure 2C).  Most study participants were also on multiple anti-glaucoma eye drops 
with a mean of 3.6 in the fibrotic group and 3.8 in the non-fibrotic group, difference = 
0.2, 95% CI: -0.2-0.7, p = .550 (Figure 2D).  A high percentage of fibrotic and non-
fibrotic participants was on topical beta blockers, prostaglandin analogues, carbonic 
anhydrase inhibitors, alpha agonists and oral acetazolamide (Figure 2E). 
 
Genotype-phenotype correlations of the IL-6 and PRG4 genes in fibrotic and non-
fibrotic conjunctival fibroblasts 
We next established fibrotic fibroblast (FF3, FF13, FF14, FF15, FF16, FF17) and non-
fibrotic fibroblast (NF1, NF4, NF7, NF8) primary cell lines from conjunctival tissues 
collected from ten patients in the study (see eTable 2 in the Supplement).  We 
performed real-time quantitative PCR to compare the IL-6 and PRG4 genes in FF and 
NF cell lines.  The IL-6 gene was upregulated in FF cell lines (0.040) compared to NF 
cell lines (0.011), difference = 0.029, 95% CI: 0.015-0.043, p = .003.  FF14 and FF16 
had the highest IL-6 gene expression while NF4 and NF7 had the lowest IL-6 gene 
expression (Figure 3A).  The PRG4 gene was also downregulated in FF cell lines 
(0.002) compared to NF cell lines (0.109), difference = 0.107, 95% CI: 0.104-0.110, p 
= .033.  NF1 and NF4 had the highest PRG4 gene expression while FF13 and FF15 had 
the lowest PRG4 gene expression (Figure 3B). 
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We also performed Spearman’s correlation between the IL-6 or PRG4 gene and the 
detailed clinical phenotype of patients.  The Spearman’s correlation coefficient r ranges 
in value from -1 to +1.  The larger the absolute value of the coefficient, the stronger the 
correlation between the variables.  A positive r indicates a positive relationship 
between the two variables whereas a negative r indicates a negative relationship.  We 
found a strong correlation between the IL-6 gene and the number of glaucoma surgeries 
(r = .94, p < .001) (Figure 3C) and logMAR visual acuity (r = .64, p = .026) (Figure 
3D).  There was also a moderate correlation between the PRG4 gene and the number of 
glaucoma surgeries (r = -.72, p = .005) (Figure 3E) and logMAR visual acuity (r = -.62, 
p = .026) (Figure 3F).  However, we found no correlations between the IL-6 or PRG4 
gene and the central bleb area, maximal bleb area, bleb height, and bleb vascularity 
(see eTable 3 in the Supplement).  There were also no correlations between the IL-6 or 
PRG4 gene and the patient age, IOP, cup disc ratio, and number of anti-glaucoma eye 
drops (see eTable 3 in the Supplement). 
 
Fibrotic conjunctival tissues express increased IL-6 and decreased PRG4 proteins 
We further stained fibrotic and non-fibrotic conjunctival tissues from glaucoma study 
participants for IL-6 and PRG4 protein expression.  Fibrotic conjunctival tissues post 
glaucoma surgery undergo marked histopathological changes compared to non-fibrotic 
conjunctival tissues.  Similar to the gene expression patterns, fibrotic conjunctival 
tissues expressed increased IL-6 and decreased PRG4 protein staining compared to 
non-fibrotic conjunctival tissues (Figures 4A and 4B). 
In addition, we stained the FF and NF cell lines to compare the distribution of the IL-6 
and PRG4 proteins in fibrotic and non-fibrotic conjunctival fibroblasts.  FF cell lines 
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had a higher proliferative rate than NF cell lines but there were overall no differences 
in cell morphology between the two groups.  There was a mixture of nuclear and 
cytoplasmic IL-6 and PRG4 staining pattern in both FF and NF cell lines (Figures 5A 
and 5B).  FF cell lines showed increased IL-6 staining compared to NF cell lines.  
FF14 and FF16 had the highest IL-6 staining while NF1 and NF4 had the lowest IL-6 
staining (Figure 5C).  We, however, did not find any differences in PRG4 staining 
between FF and NF cell lines (Figure 5D).  This could potentially be due to the 
sensitivity and specificity of the PRG4 antibody used in the study. 
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Discussion 
Deep clinical phenotyping and the use of specific tissue biomarkers represent key 
aspects of personalized medicine in ocular fibrosis (14).  In a previous study, we have 
shown that there is a distinct fibrosis gene signature in the conjunctiva after glaucoma 
surgery and the RNA signature revealed an upregulation and downregulation of the IL-
6 and PRG4 genes, respectively, in fibrotic human conjunctival fibroblasts (19).  Using 
detailed genotype-phenotype comparisons, we show here that there is a strong 
correlation between the IL-6 or PRG4 gene with the number of glaucoma surgeries and 
logMAR visual acuity.  Fibrotic conjunctival tissues post glaucoma surgery also 
express increased IL-6 and decreased PRG4 protein staining compared to non-fibrotic 
conjunctival tissues. 
Our results are consistent with important mechanistic pathways in conjunctival fibrosis, 
namely extracellular matrix remodelling and the inflammatory response.  The 
extracellular matrix component PRG4 is a serum response factor (SRF) target gene 
(20).  SRF is a master regulator of cytoskeletal gene expression (20, 21) and the 
Myocardin-related transcription factor/ Serum response factor (MRTF/SRF) pathway 
has been linked to ocular (22-24), vascular (25), skin (26), and lung fibrosis (27).  
PRG4 also binds to Toll-like receptors (TLRs) and plays an important anti-
inflammatory role in downstream signalling pathways, such as IL-6 (28-30).  Multiple 
TLRs can initiate an IL-6 transcriptional response (31).  IL-6 is a potent inflammatory 
cytokine and signal transduction involves the activation of JAK (Janus kinase) tyrosine 
kinase family members, leading to the activation of transcription factors of the STAT 
(signal transducers and activators of transcription) family (32).  Another major 
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signalling pathway for IL-6 is the Ras-MEK (MAPK/ERK kinase)-MAPK (mitogen-
activated protein kinase) cascade (32). 
Inflammation is a major risk factor for scarring after trabeculectomy surgery and 
increased inflammatory cells in the conjunctival tissues of patients with previous 
glaucoma surgery is associated with an increased risk of conjunctival scarring (33, 34).  
Afro-Caribbean patients also represent a high-risk group for conjunctival scarring and 
the increased number of conjunctival macrophages may partially explain the tendency 
for a lower success rate of filtration surgery in this group of patients (35).  In addition, 
long-term treatment with multiple anti-glaucoma eye drops has been identified as a 
significant risk factor for failure in trabeculectomy as it causes subclinical conjunctival 
inflammation with increased macrophages and lymphocytes in the conjunctival 
epithelium (36, 37). 
We report here an upregulation of the IL-6 gene in fibrotic human conjunctival 
fibroblasts after glaucoma filtration surgery.  Higher IL-6 levels also correlated 
strongly with multiple failed glaucoma surgeries and worse visual acuities in glaucoma 
patients.  Trachoma is another conjunctival scarring disease and IL-6 is overexpressed 
in scarring trachoma fibroblasts (38).  Moreover, IL-6 is an important immune 
mediator and a genome-wide association study further suggests that the genetic 
associations with trachoma scarring might be focussed on processes relating to the 
immune system (39).  Similarly, increased IL-6 has been found in dermal interstitial 
blister fluid from systemic sclerosis patients (40).  High IL-6 expression in early 
diffuse cutaneous systemic sclerosis patients is also associated with more severe skin 
involvement at three years and worse long-term survival than in those without elevated 
IL-6 levels (41). 
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In this study, we also found a downregulation of the PRG4 gene in fibrotic human 
conjunctival fibroblasts after glaucoma filtration surgery.  Lower PRG4 levels 
correlated moderately with multiple failed glaucoma surgeries and worse visual 
acuities in patients.  PRG4 is an important biological modifier that regulates processes 
such as tissue development, homeostasis, inflammation, innate immune response, and 
wound healing (42, 43).  Chronic obstructive pulmonary disease (COPD) is 
characterized by a progressive loss of lung function that is caused by repeated 
pulmonary inflammation (44).  Other studies have shown that serum PRG4 correlated 
strongly with the one-year change in predicted lung forced vital capacity and is a 
diagnostic biomarker in COPD patients (45). 
New biomarkers of fibrosis will provide sensitive and reproducible means of targeting 
and personalizing therapy, as well as assessing disease response in the future.  The 
drug pirfenidone decreased IL-6 levels (46) and reduced disease progression in patients 
with idiopathic pulmonary fibrosis (47).  Tocilizumab, a monoclonal antibody against 
IL-6, did not show a significant reduction in skin thickening but there was evidence of 
reduced decline in lung forced vital capacity in a Phase 2 clinical trial in systemic 
sclerosis patients (48). 
 
Limitations 
As this is a cross-sectional study, it is not possible to determine if the observed 
differences in IL-6 and PRG4 expression in fibrotic and non-fibrotic cell lines precede 
fibrosis, rather than being the consequence of developing fibrosis.  A future 
longitudinal study of first-time surgery patients with multiple post-operative measures 
of tissue biomarkers will be necessary to validate the predictive relationship desired for 
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clinically useful biomarkers.  Another limitation is the relatively small sample size and 
we are setting up a fibrosis biobank of tissues to validate our results in larger 
longitudinal studies in the future. 
 
Conclusions 
In this cross-sectional study, we have shown that IL-6 and PRG4 are upregulated and 
downregulated, respectively, in fibrotic human conjunctiva post glaucoma filtration 
surgery, and correlated strongly with the number of glaucoma surgeries and logMAR 
visual acuity.  Confirmation from future longitudinal studies are needed to have greater 
confidence that IL-6 and PRG4 are potential novel tissue biomarkers of disease 
severity and prognosis in conjunctival fibrosis after glaucoma surgery. 
20 
 
Author Contributions: Dr Yu-Wai-Man had full access to all the data in the study and 
takes responsibility for the integrity of the data and the accuracy of the data analysis. 
Study concept and design: Yu-Wai-Man. 
Acquisition, analysis, and/or interpretation of data: Yu-Wai-Man, Tagalakis, Meng, 
Bouremel, Lee, Virasami. 
Drafting of the manuscript: Yu-Wai-Man. 
Creation of figure illustrations: Yu-Wai-Man, Bouremel, Lee. 
Critical revision of the manuscript for important intellectual content: All authors. 
Statistical analysis: Yu-Wai-Man, Bouremel, Lee. 
Obtained funding: Yu-Wai-Man, Khaw. 
Administrative, technical, or material support: Yu-Wai-Man, Tagalakis, Meng 
Study supervision: Yu-Wai-Man, Khaw, Hart. 
 
Conflict of Interest Disclosures: All authors have completed and submitted the 
ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported. 
 
Funding/Support: This research was supported by the National Institute for Health 
Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS 
Foundation Trust and UCL Institute of Ophthalmology, the Medical Research Council, 
and Moorfields Eye Charity. 
 
Role of the Funder/Sponsor: The funding sources had no role in the design or 
conduct of the study; collection, management, analysis, and interpretation of the data; 
21 
 
preparation, review, or approval of the manuscript; and decision to submit the 
manuscript for publication. 
22 
 
Figure legends 
Figure 1. All patients in the previously operated group had marked bleb scarring 
and vascularization. 
A, Representative scarred and vascularized blebs after glaucoma filtration surgery. B, 
Central bleb area, maximal bleb area, and bleb height were graded on a scale of 1 to 5 
(1 = 0%, 2 = 25%, 3 = 50%, 4 = 75%, 5 = 100%). Bleb vascularity was graded on a 
scale of 1 to 5 (1 = avascular, 2 = normal, 3 = mild, 4 = moderate, 5 = severe 
hyperaemia). Results show mean ± SEM. 
 
Figure 2. Clinical phenotype of fibrotic (n = 28) and non-fibrotic (n = 14) patients. 
A, LogMAR visual acuity. B, Intraocular pressure. C, Cup Disc ratio. D, Number of 
anti-glaucoma eye drops. Results show mean ± SEM, p values. E, Percentage of 
patients on different types of anti-glaucoma treatment. 
 
Figure 3. Genotype-phenotype correlations of IL-6 and PRG4 genes in fibrotic and 
non-fibrotic conjunctival fibroblasts. 
A, IL-6 and B, PRG4 genes were measured by real-time quantitative PCR. All mRNA 
values were normalized relative to that of GAPDH and triplicate experiments were 
performed for each condition. Results show mean ± SEM. Spearman’s correlation r 
between C, IL-6 gene and number of glaucoma surgeries. D, IL-6 gene and logMAR 
visual acuity. E, PRG4 gene and number of glaucoma surgeries. F, PRG4 gene and 
logMAR visual acuity. The values in more than one cell line were the same for PRG4 
gene expression. 
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Figure 4. Fibrotic conjunctival tissues express increased IL-6 and decreased 
PRG4 proteins compared to non-fibrotic conjunctival tissues. 
Sections of fibrotic and non-fibrotic conjunctiva tissues were stained for A, IL-6 and B, 
PRG4 proteins. Black arrows indicate areas of high IL-6 and PRG4 staining. Scale bar 
= 50 m. 
 
Figure 5. Fibrotic fibroblast cell lines express increased IL-6 protein compared to 
non-fibrotic cell lines. 
FFs and NFs were seeded onto coverslips and stained for A, IL-6 and B, PRG4. Scale 
bar = 30 m. Fluorescent intensity of C, IL-6 and D, PRG4 staining were calculated 
using a bespoke image processing algorithm written in MATLAB. Three randomly 
chosen fields were imaged per condition. Results show mean ± SEM. 
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